Shares of health-care companies fell as traders rotated out of defensive areas into rate-sensitive financial stocks.
AstraZeneca said its Fasenra asthma treatment has received European Union approval following late stage trials.
Continue Reading Below
The results of a drug trial jointly operated by Merck and Incyte, due to be released by midyear, will help shape the future of drug makers' immunotherapy products, a promising line of cancer treatments.
Rob Curran, email@example.com
(END) Dow Jones Newswires
January 10, 2018 16:57 ET (21:57 GMT)